Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    4-Chlorokynurenine

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    VistaGen fails phase 2 depression trial, sparking stock rout
    VistaGen fails phase 2 depression trial, sparking stock rout

    15 Nov 2019

    // Nick P.Taylor FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/vistagen-fails-phase-2-depression-trial-sparking-stock-rout

    Nick P.Taylor FIERCE BIOTECH
    15 Nov 2019
    Share Share
    Microcap biotech VistaGen turned to pennystock after PhII result depression drug
    Microcap biotech VistaGen turned to pennystock after PhII result depression drug

    03 May 2019

    // Amber Tong ENDPTS

    https://endpts.com/microcap-biotech-vistagen-turned-to-pennystock-after-phii-results-show-its-depression-drug-doesnt-work-solo/

    Amber Tong ENDPTS
    03 May 2019
    Share Share
    VistaGen - Nanocap CNS Drug Chasing Ketamine Fame
    VistaGen - Nanocap CNS Drug Chasing Ketamine Fame

    21 May 2018

    // SEEKING ALPHA

    https://seekingalpha.com/article/4158084-vistagen-nanocap-cns-drug-chasing-ketamine-fame

    SEEKING ALPHA
    21 May 2018
    Share Share
    VistaGen Therapeutics Initiates Phase 2 Study of AV-101 for Major Depressive Disorder
    VistaGen Therapeutics Initiates Phase 2 Study of AV-101 for Major Depressive Disorder

    05 Apr 2018

    // PRESS RELEASE

    http://www.marketwired.com/press-release/vistagen-therapeutics-initiates-phase-2-study-av-101-major-depressive-disorder-nasdaq-vtgn-2246564.htm

    PRESS RELEASE
    05 Apr 2018
    Share Share
    Investors unimpressed with VistaGen update on AV-101; shares down 16%
    Investors unimpressed with VistaGen update on AV-101; shares down 16%

    30 Dec 2017

    // Douglas House SEEKING ALPHA

    https://seekingalpha.com/news/3326447-investors-unimpressed-vistagen-update-avminus-101-shares-16-percent

    Douglas House SEEKING ALPHA
    30 Dec 2017
    Share Share
    How Ketamine could cure depression
    How Ketamine could cure depression

    30 Jan 2017

    // DRUG TARGET REVIEW

    https://www.drugtargetreview.com/article/21644/ketamine-depression/

    DRUG TARGET REVIEW
    30 Jan 2017
    Share Share